Q-omics provides the consensus-scored IL18R1 profile across patient tissues and cancer cell-line models. IL18R1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, IL18R1 is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, IL18R1 RNA expression shows 19,639 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, KICH, and GBM as cancer lineages where IL18R1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IL18R1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IL18R1 survival associations across molecular data types. IL18R1 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (6) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IL18R1 RNA expression–survival associations across cancer types. High IL18R1 expression shows unfavorable associations in UVM and KIRP, but favorable associations in KIRC, SKCM, BLCA and CESC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for IL18R1 RNA expression.
This table summarizes IL18R1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for IL18R1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IL18R1 shows lower tumor expression in KICH, LUSC, LUAD and LIHC and higher tumor expression in KIRC and HNSC. The KICH box plot shows higher IL18R1 RNA expression in normal versus tumor tissue (log2 FC = −1.796, t-test p < 0.001).
This table shows molecular features associated with IL18R1 in patient tissues and cancer cell lines. In patient samples, IL18R1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, IL18R1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BONE.
